Tango Therapeutics Inc (NASDAQ:TNGX) has a beta value of 0.89 and has seen 2.67 million shares traded in the last trading session. The company, currently valued at $555.01M, closed the last trade at $5.18 per share which meant it gained $0.02 on the day or 0.39% during that session. The TNGX stock price is -151.16% off its 52-week high price of $13.01 and 2.12% above the 52-week low of $5.07. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.34 million shares traded. The 3-month trading volume is 1.02 million shares.

The consensus among analysts is that Tango Therapeutics Inc (TNGX) is Buy stock at the moment, with a recommendation rating of 1.11. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.37.

Tango Therapeutics Inc (NASDAQ:TNGX) trade information

Sporting 0.39% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the TNGX stock price touched $5.18 or saw a rise of 13.67%. Year-to-date, Tango Therapeutics Inc shares have moved -47.68%, while the 5-day performance has seen it change -13.67%. Over the past 30 days, the shares of Tango Therapeutics Inc (NASDAQ:TNGX) have changed -25.89%. Short interest in the company has seen 8.9 million shares shorted with days to cover at 8.71.

Wall Street analysts have a consensus price target for the stock at $13, which means that the shares’ value could jump 60.15% from current levels. The projected low price target is $13.0 while the price target rests at a high of $18.0. In that case, then, we find that the current price level is -247.49% off the targeted high while a plunge would see the stock gain -150.97% from current levels.

Tango Therapeutics Inc (TNGX) estimates and forecasts

Figures show that Tango Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -34.01% over the past 6 months, with this year growth rate of -17.59%, compared to 17.30% for the industry. Revenue growth from the last financial year stood is estimated to be 15.80%.

10 analysts offering their estimates for the company have set an average revenue estimate of 7.81M for the current quarter. 10 have an estimated revenue figure of 8.17M for the next ending quarter. Year-ago sales stood 10.73M and 5.43M respectively for this quarter and the next, and analysts expect sales will shrink by -27.20% for the current quarter and 15.80% for the next.

TNGX Dividends

Tango Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Tango Therapeutics Inc (NASDAQ:TNGX)’s Major holders

Insiders own 12.87% of the company shares, while shares held by institutions stand at 88.99% with a share float percentage of 102.14%. Investors are also buoyed by the number of investors in a company, with Tango Therapeutics Inc having a total of 179.0 institutions that hold shares in the company. The top two institutional holders are TRV GP IV, LLC with over 19.2 million shares worth more than $164.75 million. As of 2024-06-30, TRV GP IV, LLC held 17.751% of shares outstanding.

The other major institutional holder is ECOR1 CAPITAL, LLC, with the holding of over 13.33 million shares as of 2024-06-30. The firm’s total holdings are worth over $114.38 million and represent 12.3237% of shares outstanding.